Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Laboratory Corporation of America Holdings(LH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LH
09/25/2026: LH (2-star) is currently NOT-A-BUY. Pass it for now.
Laboratory Corporation of America Holdings is a significant provider of clinical diagnostics and drug development services. The company benefits from a dual-engine business model that combines stable, high-volume testing with growth-oriented pharmaceutical research support. Its extensive patient service network provides a competitive edge, though success relies on managing healthcare reimbursement trends and integrating complex business units. While facing risks from hospital consolidation and regulatory pricing changes, the company serves as a defensive yet innovative player in the healthcare sector. It may suit investors looking for exposure to stable healthcare fundamentals and the long-term trend of outsourcing drug development.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is steady rather than explosive, driven by aging demographics and pharmaceutical R&D outsourcing. |
| Momentum investor | Weak fit | The stock tends to trade based on long-term healthcare fundamentals rather than rapid short-term price momentum. |
| Value investor | Strong fit | The company often trades at reasonable multiples relative to its stable cash flows and market position. |
| Dividend investor | Mixed fit | While stable, the yield is modest as the company prioritizes reinvestment over high dividend payouts. |
| Low-risk investor | Strong fit | The essential nature of laboratory diagnostics provides a degree of defensive stability to the investment. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Broader market trends and healthcare sentiment can influence share price swings. |
| Valuation risk | Low | The stock typically trades at valuation multiples that reflect its stable, utility-like business model. |
| Competition risk (traditional labs and CROs) | Medium | Maintaining margins requires constant efficiency gains against established diagnostic and research competitors. |
| Business quality | Strong | The company provides essential healthcare infrastructure that is difficult to replicate. |
| Dividend income | Low | Investors should not rely on the stock for significant income generation compared to high-yield sectors. |
| Execution risk | Medium | Success depends on the effective integration of varied diagnostic and biopharma business segments. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 9.28% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 25.06B USD | Price to earnings Ratio 25.12 | 1Y Target Price 344.81 |
Price to earnings Ratio 25.12 | 1Y Target Price 344.81 | ||
Volume (30-day avg) 762.8K shares | Beta 0.85 | 52 Weeks Range 242.07 - 341.06 | Updated Date 09/25/2026 |
52 Weeks Range 242.07 - 341.06 | Updated Date 09/25/2026 | ||
Dividends yield (FY) 0.95% | Basic EPS (TTM) 12.3 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostics | Clinical laboratory testing services for physicians and hospital systems. | This is a reliable 'bread and butter' business that provides steady demand. |
| Biopharma Services | Clinical trial support, central lab testing, and drug development consulting. | This segment offers higher growth potential tied to global pharmaceutical R&D spending. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 25.12 | Forward PE 16.16 | Enterprise Value 31.28B | Price to Sales(TTM) 1.75 |
Enterprise Value 31.28B | Price to Sales(TTM) 1.75 | ||
Enterprise Value to Revenue 2.18 | Enterprise Value to EBITDA 14.5 | Shares Outstanding 81.10M | Shares Floating 80.72M |
Shares Outstanding 81.10M | Shares Floating 80.72M | ||
Percent Insiders 0.35 | Percent Institutions 101.89 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Laboratory Corporation of America Holdings
Exchange NYSE | Headquarters Burlington, NC, United States | ||
IPO Launch date 1990-03-29 | President, CEO & Chairman Mr. Adam H. Schechter | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 71000 | Website https://www.labcorp.com |
Full time employees 71000 | Website https://www.labcorp.com | ||
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.